BRIEF-HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment

Reuters
02 Dec 2024

Dec 2 (Reuters) - Soligenix Inc :

* HYBRYTE™ CLINICAL RESULTS DEMONSTRATE CONTINUED IMPROVEMENT POST-TREATMENT

* SOLIGENIX: 1 OF 5 PATIENTS RECEIVING VALCHLOR HAD TO BE WITHDRAWN FROM TRIAL DUE TO A CLINICALLY SIGNIFICANT ALLERGIC CONTACT DERMATITIS

* SOLIGENIX INC: HYBRYTE WAS WELL TOLERATED IN ALL PATIENTS

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10